M&A

CDT Equity partners with a top advisory firm to license its drug-enhancing tech, tackling the patent cliff while managing a novel Bitcoin treasury strategy.

Hyatt finalizes a $2B asset sale to Tortuga Resorts, advancing its asset-light strategy while navigating hurricane recovery in the Caribbean.

The regional bank sold $360M in low-yield securities, accepting a major one-time loss to reinvest for higher returns and a stronger 2026 outlook.

With industry veteran Kevin Muskat at the helm, Leon Capital Group's new advisory practice promises M&A guidance free from audit firm conflicts.

As Uxin prepares to report Q3 results, all eyes are on its ambitious superstore strategy and whether it can drive profitability in a complex market.

BrightView Holdings declared its eighth straight cash dividend, a move signaling financial discipline even as it navigates revenue challenges and stock volatility.

Oak Hill Advisors' record fundraise underscores a major shift in corporate finance, as private credit becomes the go-to capital source for large-cap firms.

A regulatory filing reveals a key investor's move in the Avadel bidding war, exposing the intense M&A hunger driving the future of health tech.

Abeona Therapeutics' new treatment center for ZEVASKYN marks a strategic leap in gene therapy access, but what does it mean for patients and the market?

Emera renewed its C$600M equity program. We dive into the $20B plan driving this move and what it means for the future of energy grids and investors.

Swedish innovator SciBase is overhauling its capital structure with a complex warrant buyback. Is this a strategic masterstroke or a necessary defensive play?

Pershing Square's latest share repurchase is more than routine; it's a strategic move to close a stubborn valuation gap and signal deep confidence.